These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 1389491

  • 1. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients.
    Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ.
    Eur J Cancer; 1992; 28A(10):1712-6. PubMed ID: 1389491
    [Abstract] [Full Text] [Related]

  • 2. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
    MacNeill FA, Jacobs S, Dowsett M, Lonning PE, Powles TJ.
    Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
    MacNeill FA, Jacobs S, Lønning PE, Powles TJ, Dowsett M.
    Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
    [Abstract] [Full Text] [Related]

  • 5. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC, Dowsett M, Hedley A, Gazet JC, Ford HT, Coombes RC.
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [Abstract] [Full Text] [Related]

  • 6. Evidence for separate sites for aromatisation of androstenedione and 16 alpha-hydroxyandrostenedione in human placental microsomes.
    Purohit A, Oakey RE.
    J Steroid Biochem; 1989 Sep; 33(3):439-48. PubMed ID: 2779235
    [Abstract] [Full Text] [Related]

  • 7. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
    Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, McNeil F, Johannessen DC, Powles TJ.
    Breast Cancer Res Treat; 1992 Sep; 23(1-2):57-62. PubMed ID: 1446052
    [Abstract] [Full Text] [Related]

  • 8. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.
    Jacobs S, Lønning PE, Haynes B, Griggs L, Dowsett M.
    J Enzyme Inhib; 1991 Sep; 4(4):315-25. PubMed ID: 1669831
    [Abstract] [Full Text] [Related]

  • 9. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.
    Coombes RC, Hughes SW, Dowsett M.
    Eur J Cancer; 1992 Sep; 28A(12):1941-5. PubMed ID: 1419285
    [Abstract] [Full Text] [Related]

  • 10. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostenedione.
    Reed MJ, Owen AM, Lai LC, Coldham NG, Ghilchik MW, Shaikh NA, James VH.
    Int J Cancer; 1989 Aug 15; 44(2):233-7. PubMed ID: 2759729
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and metabolism of formestane in breast cancer patients.
    Lønning PE, Geisler J, Johannessen DC, Gschwind HP, Waldmeier F, Schneider W, Galli B, Winkler T, Blum W, Kriemler HP, Miller WR, Faigle JW.
    J Steroid Biochem Mol Biol; 2001 Apr 15; 77(1):39-47. PubMed ID: 11358673
    [Abstract] [Full Text] [Related]

  • 13. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
    Reed MJ, Lai LC, Owen AM, Singh A, Coldham NG, Purohit A, Ghilchik MW, Shaikh NA, James VH.
    Cancer Res; 1990 Jan 01; 50(1):193-6. PubMed ID: 2293555
    [Abstract] [Full Text] [Related]

  • 14. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients.
    Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC.
    Cancer Res; 1989 Mar 01; 49(5):1306-12. PubMed ID: 2917360
    [Abstract] [Full Text] [Related]

  • 15. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
    Dowsett M, Coombes RC.
    Breast Cancer Res Treat; 1994 Mar 01; 30(1):81-7. PubMed ID: 7949207
    [Abstract] [Full Text] [Related]

  • 16. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
    Dowsett M, Doody D, Miall S, Howes A, English J, Coombes RC.
    Breast Cancer Res Treat; 1999 Jul 01; 56(1):25-34. PubMed ID: 10517340
    [Abstract] [Full Text] [Related]

  • 17. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
    Miller WR, Stuart M, Sahmoud T, Dixon JM.
    Br J Cancer; 2002 Oct 21; 87(9):950-5. PubMed ID: 12434282
    [Abstract] [Full Text] [Related]

  • 18. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.
    Dowsett M, Santner SJ, Santen RJ, Jeffcoate SL, Smith IE.
    Br J Cancer; 1985 Jul 21; 52(1):31-5. PubMed ID: 4015950
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects.
    Geisler J, Johannessen DC, Anker G, Lønning PE.
    Eur J Cancer; 1996 May 21; 32A(5):789-92. PubMed ID: 9081355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.